JPRN-UMIN000018265招募中未知
Direct comparison of TOfogliflozin and iPragliflozin on hyper-hypoglycemia using Continuous Glucose Monitoring system (TOP-CGM) - Tofogliflozin and continuous glucose monitoring
niversity of Occupational and Environmental Health0 个研究点目标入组 30 人开始时间: 2015年7月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Has hypersensitivity to tofogliflozin and ipragliflozin or any other excipient of them (2) With severe ketosis, diabetic coma, or precoma (3) With severe infection, pre or post-surgery, and serious trauma (4)Has arteriosclerotic disease (myocardial infarction, stroke and so on) and history of them (5) End-stage renal disease (ESRD) undergoing hemodialysis (6) With severe liver dysfunction (7) Has insulin therapy (8) Entered already with another clinical trials (9) Considered as inadequate by the investigator
研究者
相似试验
已完成
不适用
Two-way crossover comparison of tofogliflozin and canagliflozin using continuous glucose monitoring.Type 2 diabetesJPRN-UMIN000024969Kitasato University School of Pharmacy20
已完成
不适用
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
招募中
4 期
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70
未知
1 期
Drug-drug interaction study (2) of TofoglifloziJPRN-jRCT2080221710Chugai Pharmaceutical Co., Ltd.87
未知
1 期
Drug-drug interaction study (1) of TofoglifloziType 2 diabetsJPRN-jRCT2080221599Chugai Pharmaceutical Co., Ltd.90